TScan Therapeutics, Inc. (NASDAQ:TCRX) shares are trading higher in the premarket session on Thursday. The firm announced a significant financing deal, entering into a securities purchase agreement ...
WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...
Analysts' ratings for TScan Therapeutics (NASDAQ:TCRX) over the last quarter vary from bullish to bearish, as provided by 5 analysts. The table below provides a snapshot of their recent ratings, ...
WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...
WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) ...
TScan Therapeutics announces $30 million investment from Lynx1 Capital Management for pre-funded warrants, extending cash runway into early 2027. TScan Therapeutics, Inc. has announced a securities ...
TScan Therapeutics (TCRX) is a very important biotech to watch closely in the coming year. The reason why is because it is in the process of developing its T-Cell Receptor [TCR] engineered T-cell [TCR ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback